361. Evaluation of Resistance to Nirmatrelvir/ritonavir in Evaluation of Protease Inhibition for COVID-19 (EPIC) High-Risk and Standard-Risk Clinical Trials

BACKGROUND: Nirmatrelvir/ritonavir administered twice daily for 5 days (5D) (within 5 days of symptom onset) resulted in a clinically and statistically significant (6% absolute and 86% relative) risk reduction in COVID-19 related hospitalization or all cause death through Day 28 [1]. COVID-19 reboun...

Descripción completa

Detalles Bibliográficos
Autores principales: Lynn Baniecki, Mary, Guan, Shunjie, Wang, Zhenyu, Chen, Yan, Bao, Weihang, He, Wen, Dushin, Elizabeth, Hyde, Craig, Zhu, Yuao, Cardin, Rhonda D, Hammond, Jennifer, Menon, Sandeep, Allerton, Charlotte, Soares, Holly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678225/
http://dx.doi.org/10.1093/ofid/ofad500.431

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678225/
http://dx.doi.org/10.1093/ofid/ofad500.431

Ejemplares similares